Global Research Trends and Hotspots Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies
10.3870/j.issn.1004-0781.2024.04.024
- VernacularTitle:前蛋白转化酶枯草溶菌素9单克隆抗体全球研究趋势及热点分析
- Author:
Ning JIANG
1
;
Wenshuang MENG
;
Lina CHEN
;
Yaodong YAN
;
Mingfen WU
Author Information
1. 北京市健宫医院药剂科,北京 100054
- Keywords:
Proprotein convertase subtilisin/kexin type 9 monoclonal antibody;
Evolocumab;
Alirocumab;
Visual litera-ture analysis software;
Bibliometrics
- From:
Herald of Medicine
2024;43(4):630-635
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the global research status,hotspots,and frontiers of proprotein convertase subtilisin/Kexin type 9(PCSK9)monoclonal antibodies,and to provide a reference for related scientific research and the rational drug use in clinical practice in China.Methods The research literature related to PCSK9 monoclonal antibody included in the Web of Science database was searched for the period from January 2011 to February 2022,and the literature included in the study was visually analyzed by the CiteSpace software.Results A total of 723 articles were included,and the annual number of publica-tions showed an overall upward trend.The top three countries were the United States,France,and the United Kingdom.Sanofi was the organization with the largest number of articles,and the organization with the highest citation of articles was Brigham and Women's Hospital.The hotspots of research mainly included the use of PCSK9 monoclonal antibody in the treatment of patients with hypercholesterolemia,patients who do not tolerate statins,patients with high cardiovascular risk,and the efficacy and safety of PCSK9 monoclonal antibody in lipid-lowering therapy combined statins;The frontiers of research in recent two years is the appli-cation of PCSK9 monoclonal antibodies in patients with acute coronary syndrome and the clinical benefits after reducing the level of lipoprotein(a).Conclusion A large number of studies have confirmed the efficacy and safety of PCSK9 monoclonal anti-bodies in reducing blood lipids,but there is still a lack of research on its economics and application in special populations,which should be the focus of future research.
